Mesa Laboratories, Inc.
NASDAQ•MLAB
CEO: Mr. Gary M. Owens
Sector: Technology
Industry: Hardware, Equipment & Parts
Listing Date: 1984-02-29
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Contact Information
Market Cap
$441.98M
P/E (TTM)
118.5
21.4
Dividend Yield
0.8%
52W High
$131.20
52W Low
$55.45
52W Range
Rank32Top 23.6%
4.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2026 Data
Revenue
$65.13M+3.64%
4-Quarter Trend
EPS
$0.66-312.90%
4-Quarter Trend
FCF
$18.02M+2.25%
4-Quarter Trend
2026 Q3 Earnings Highlights
Key Highlights
Quarterly Net Income Soars Quarterly net income reached $3.63M, showing 316.6% increase compared to prior period loss of $1.68M.
Nine Month Revenue Growth Nine month revenues totaled $185.41M, marking 3.7% growth, while Net Income grew 111.1% to $10.85M.
Working Capital Turns Positive Working capital improved to $51.2M from negative $(61.3)M after settling $97.5M convertible notes debt during nine months.
Basic Earnings Per Share Doubles Basic EPS for nine months was $1.97, significantly higher than $0.95 reported in the comparable prior period.
Risk Factors
China Market Uncertainty Persists Clinical Genomics revenue declined 6.7% for nine months due to China macroeconomic uncertainty and heightened trade tensions.
Genomics Unit Impairment Risk Clinical Genomics unit remains sensitive to impairment; fair value exceeded carrying value by 40% in recent annual test.
Currency and Tariff Margin Pressure Weak USD and tariffs reduced consolidated gross profit margin by 0.8 points for nine months, impacting several divisions.
G&A Expense Rises General and administrative expense rose 3.4% for nine months, driven by higher allowance for uncollectible China receivables.
Outlook
Credit Facility Spread Reduced Amended Credit Facility reduced interest spread, expected to save approximately $0.4M annually on current debt balances.
Focus on Core Growth Future growth relies on expanding customer base and integrating acquisitions, focusing on Biopharma and Sterilization segments.
New Tax Legislation Incorporated Incorporated provisions of OBBBA into tax provision, resulting in reduction of U.S. current tax expense for fiscal year 2026.
Continued Dividend Payments Company continues regular quarterly dividend payments of $0.16 per share, maintaining commitment to shareholder returns.
Peer Comparison
Revenue (TTM)
$7.02B
$3.04B
$407.23M
Gross Margin (Latest Quarter)
73.1%
68.2%
64.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| VPG | $540.41M | 102.0 | 1.6% | 14.0% |
| LPTH | $459.38M | -21.6 | -70.2% | 6.9% |
| MLAB | $441.98M | 118.5 | 2.1% | 23.8% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.6%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:May 26, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data